PUBLISHER: Grand View Research | PRODUCT CODE: 1888579
PUBLISHER: Grand View Research | PRODUCT CODE: 1888579
The global anatomic pathology market size was estimated at USD 34.72 billion in 2024 and is projected to reach USD 80.78 billion by 2033, growing at a CAGR of 9.79% from 2025 to 2033. Some of the major factors driving the market growth are rising global cancer and chronic disease burden, growing adoption of precision and personalized medicine, and digital pathology and artificial intelligence (AI) advancements.
For instance, in July 2025, PathAI (U.S.) launched the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories powered by PathAI's AISight 1 Image Management System (IMS). The PPN is intended to provide early access to the most recent AI-powered pathology solutions developed by PathAI in collaboration with the biopharma industry, to allow participating laboratories to monetize real-world pathology data, to support biopharma-sponsored evidence generation studies, and to enable novel clinical development strategies that leverage AI-pathology. Furthermore, an aging population and rising healthcare expenditure fuel the growth of the global anatomic pathology industry. As per the World Population Prospects 2024, the world's population is expected to keep growing for another 50 or 60 years, peaking at around 10.3 billion in the mid-2080s, up from 8.2 billion in 2024.
The growth of molecular pathology and companion diagnostics (CDx) is significantly increasing the global market by allowing for more precise, personalized, and targeted approaches to disease diagnosis and treatment. Molecular pathology detects genetic, molecular, and cellular changes associated with specific diseases, most notably cancer, allowing for earlier and more accurate diagnoses. Companion diagnostics help guide the use of targeted therapies by identifying patients who are most likely to benefit from specific treatments. This combination of diagnostics and therapeutics is increasingly being used in oncology and other fields of medicine, driving demand for advanced pathology services. As pharmaceutical companies continue to invest in personalized medicine and regulatory agencies encourage the incorporation of CDx into drug development pipelines, the role of anatomic pathology is expanding beyond traditional histology to include molecular insights, accelerating market growth and innovation.
In addition to rising disease burdens and technological advancements, a number of other factors are driving the global anatomic pathology industry. The growing awareness and education of patients and healthcare providers about the importance of early and accurate diagnosis is driving up demand for pathology services. The growing number of biopsy procedures, driven by routine health screenings and preventive care programs, is increasing the demand for pathology analysis. Furthermore, the transition from hospital-based care to outpatient and specialized diagnostic centers improves pathology services' accessibility and efficiency. Favorable reimbursement policies in developed countries, as well as supportive government initiatives to strengthen diagnostic infrastructure in emerging economies, are further driving market growth.
Furthermore, strategic collaborations, mergers, and acquisitions between diagnostic labs, hospitals, and technology companies are fostering innovation and expanding service offerings across regions.
Global Anatomic Pathology Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the anatomic pathology market report based on product & service, application, end use, and region: